Mapping the comorbidome: A novel analysis of the associations between obstructive sleep apnea and its comorbidities in Colombia
Science Progress,
Год журнала:
2025,
Номер
108(2)
Опубликована: Апрель 1, 2025
Introduction
Obstructive
sleep
apnea
(OSA)
is
linked
to
a
complex
network
of
comorbidities,
including
cardiovascular,
metabolic,
neurological,
and
oncological
diseases.
The
comorbidome
visually
maps
disease
associations,
highlighting
the
interconnected
comorbidities
OSA,
whose
incidence
severity
are
strongly
correlated.
Methods
A
retrospective
cohort
study
was
conducted
between
2005
2020
identify
most
frequently
associated
with
OSA
through
comprehensive
comorbidity
map.
prevalence
each
calculated
as
percentage,
detailed
analysis
performed
examine
relationship
these
OSA.
This
graphic
represents
all
significant
associations
where
size
bubble
proportional
within
cohort,
proximity
center
reflects
strength
association.
Results
total
3043
patients
diagnosed
were
included,
whom
51.1%
(1154/3043)
had
severe
29.2%
(889/3043)
moderate
19.7%
(600/3043)
mild
average
age
57.6
years
(SD
±
15.32),
65.6%
(1995/3043)
men.
Among
hypertension
present
in
48.0%
(288/600),
53.0%
(470/889),
58.5%
(909/1554).
Renal
failure
(OR:
9.39;
95%
CI:
3.7–23.84),
cardiovascular
7.73;
3.92–15.21),
dementia
6.98;
2.85–17.11),
hemiplegia/stroke
sequelae
6.90;
2.02–23.51),
smoking
5.54;
2.74–11.21),
diabetes
4.34;
2.02–9.35)
Hemiplegia/stroke
10.11;
3.8–26.89),
9.77;
6.18–15.46),
chronic
pulmonary
7.48;
4.76–11.77),
6.80;95%
3.37–13.71)
Dementia
10.59;
6.41–17.5),
leukemia
lymphoma
7.49;
2–28.1),
7.24;
5.33–9.83),
hemiplegia
or
stroke
6.33;
3.3–12.16),
renal
6.10;
3.97–9.36)
Conclusion
prevalent
hypertension,
smoking,
disease,
higher
Additionally,
association
observed
certain
mortality,
particularly
conditions
such
dementia.
Malignant
neoplastic
diseases
related
Язык: Английский
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
Expert Opinion on Pharmacotherapy,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 2, 2024
Introduction
Traditionally,
obstructive
sleep
apnea
(OSA)
management
has
focused
on
continuous
positive
airway
pressure
therapy,
oral
appliances,
and
in
some
cases,
surgical
interventions.
However,
these
treatments
do
not
directly
address
the
underlying
metabolic
issues
contributing
to
OSA.
Glucagon-like
peptide-1
receptor
agonists
(GLP-1
RAs),
originally
developed
for
type
2
diabetes
management,
have
demonstrated
substantial
efficacy
promoting
weight.
Язык: Английский
Does the severity of obstructive sleep apnea increase the risk of cancer? Clues in apnea-hypopnea index and biomarkers
Journal of Clinical Sleep Medicine,
Год журнала:
2024,
Номер
20(9), С. 1403 - 1404
Опубликована: Сен. 1, 2024
Язык: Английский
Exploring the pharmacological mechanisms for alleviating OSA: Adenosine A2A receptor downregulation of the PI3K/Akt/HIF‑1 pathway (Review)
Biomedical Reports,
Год журнала:
2024,
Номер
22(2)
Опубликована: Ноя. 28, 2024
Obstructive
sleep
apnea
(OSA)
is
the
most
common
type
of
apnea,
which
leads
to
episodes
intermittent
hypoxia
due
obstruction
upper
airway.
A
key
feature
OSA
upregulation
and
stabilization
hypoxia‑inducible
factor
1
(HIF‑1),
a
crucial
metabolic
regulator
that
facilitates
rapid
adaptation
changes
in
oxygen
availability.
Adenosine
A2A
receptor
(A2AR),
major
adenosine
receptor,
regulates
HIF‑1
under
hypoxic
conditions,
exerting
anti‑inflammatory
properties
affecting
lipid
metabolism.
The
present
study
explored
roles
A2AR
regulation,
specifically
focusing
on
its
effects
via
PI3K/Akt/HIF‑1
pathway.
findings
enhance
our
understanding
pharmacological
potential
management
suggest
future
research
directions
exploring
clinical
applications.
Язык: Английский